Andrew Tinsley

Andrew Tinsley, MD, serves as an Associate Professor within the Department of Medicine, specifically in the Division of Gastroenterology and Hepatology, and is associated with the Center for Cannabis and Natural Product Pharmaceuticals (CCNPP). His academic and clinical work is centered on advancing the understanding and treatment of gastrointestinal disorders, particularly inflammatory bowel diseases.

Dr. Tinsley's primary research interests encompass inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, with a strong focus on abdominal pain mechanisms, emergency department utilization patterns, and the influence of lifestyle factors on disease progression and symptom management. His research also investigates genetic polymorphisms, such as SCN10A, and their role in pain perception and visceral hypoalgesia among IBD patients, contributing to personalized treatment approaches.

Recent publications (2023-2024) demonstrate a consistent emphasis on real-world data analysis, examining the economic burden of emergency department visits by IBD patients, the predictive value of abdominal pain for future healthcare resource use, and the interplay between lifestyle choices and disease activity. His collaborative work spans multiple institutions and leverages large datasets to address critical gaps in IBD management.

No scientific awards are explicitly mentioned in the available profile information.

While specific details regarding graduate student advising and grant funding are not provided, Dr. Tinsley's extensive publication record (46 outputs) and active research agenda suggest significant contributions to academic mentorship and externally funded projects within the field of gastroenterology.

Dr. Tinsley is affiliated with the Center for Cannabis and Natural Product Pharmaceuticals (CCNPP), indicating engagement in innovative research on the therapeutic potential of natural compounds, including cannabis derivatives, for gastrointestinal conditions.